期刊文献+
共找到41篇文章
< 1 2 3 >
每页显示 20 50 100
A case of locally advanced gastric cancer treated with nivolumab, trastuzumab, plus chemotherapy in a neoadjuvant setting
1
作者 Shi-Yu Jiang Yan Qin Yuan-Kai Shi 《中华医学杂志:英文版》 SCIE CAS CSCD 2019年第11期1370-1371,共2页
To the Editor:Recently,the advantages of peri-operative chemotherapy in downstaging tumor and improving patient survival have been reported. Herein, we report a case of gastric cancer patient receiving neoadjuvant che... To the Editor:Recently,the advantages of peri-operative chemotherapy in downstaging tumor and improving patient survival have been reported. Herein, we report a case of gastric cancer patient receiving neoadjuvant chemotherapy along with trastuzumab and nivolumab. 展开更多
关键词 CHEMOTHERAPY GASTRIC cancer patients TUMOR
基于网络药理学方法的左金丸治疗结直肠癌的作用机制分析 预览
2
作者 潘秋莎 杨梦蝶 +2 位作者 呼雪庆 赵明 苏式兵 《世界科学技术:中医药现代化》 CSCD 北大核心 2019年第3期512-520,共9页
目的:运用网络药理学方法探究左金丸治疗结直肠癌的潜在效应机制。方法:依托中药系统药理学分析平台收集左金丸中黄连和吴茱萸的化学成分和靶点信息,通过疾病基因库收集结直肠癌疾病基因,并通过维恩分析、蛋白互作分析以及Cytoscape的... 目的:运用网络药理学方法探究左金丸治疗结直肠癌的潜在效应机制。方法:依托中药系统药理学分析平台收集左金丸中黄连和吴茱萸的化学成分和靶点信息,通过疾病基因库收集结直肠癌疾病基因,并通过维恩分析、蛋白互作分析以及Cytoscape的可视化功能,构建化合物-靶点网络、蛋白互作(PPI)网络和成分-靶点-通路网络,分析左金丸治疗结直肠癌的效应机制。结果:从左金丸化合物-靶点网络得到234种成分和482个核心靶点(其中活性成分36个,核心靶点72个),结直肠癌基因737个,PPI网络包含50个蛋白,其主要蛋白涉及PIK3CA、AKT1、TP53、HIF-1α、BAX和MYC等。基因GO本体条目283条,涉及核质、细胞凋亡、基因表达调控等方面, KEGG通路58条,主要涉及有癌症的途径、癌症中的蛋白多糖、结肠癌、膀胱癌、乙型肝炎,以及HIF-1信号通路、PI3K信号通路和FOXO信号通路等,其结果有待进一步的实验验证。结论:结合文献报道和预测分析,左金丸可能的作用机制与以下相关:①调节机体免疫耐受能力,增强宿主免疫抵抗,抑制炎症对肠粘膜的持续性刺激,进而阻止了细胞的异常增生;②通过上调抑癌基因,下调癌症相关因子,促进肿瘤细胞发生凋亡;③降低肿瘤细胞的耐受缺氧环境,促进细胞细胞发生凋亡及上皮间质的转移。 展开更多
关键词 网络药理学 左金丸 结直肠癌 作用机制
在线阅读 下载PDF
A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma
3
作者 Peng Liu Ying Han +9 位作者 Shi-Yu Jiang Xiao-Hui He Yan Qin Lin Gui Sheng-Yu Zhou Li-Qiang Zhou Jian-Liang Yang Sheng Yang Ting-Yu Wen Yuan-Kai Shi 《中华医学杂志:英文版》 SCIE CAS CSCD 2019年第15期1807-1814,共8页
Background:Elderly patents with diffuse large B-cell lymphoma (DLBCL) have a worse prognosis than younger patients,and the optimal treatment strategy for this group remains controversial.We conducted a retrospective a... Background:Elderly patents with diffuse large B-cell lymphoma (DLBCL) have a worse prognosis than younger patients,and the optimal treatment strategy for this group remains controversial.We conducted a retrospective analysis to investigate the clinical features and outcomes of elderly patients (>60 years) and to assess the impact of clinical and molecular factors on outcome in this age group.Methods:From April 2006 to December 2012,a total of 349 elderly patients with DLBCL from the National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences,and Peking Union Medical College were included in this analysis.Patients were further divided into two age groups (61-69 years and ≥70 years).We compared clinical characteristics and outcomes between groups.Results:Of 349 total patients,204 (58.5%) were aged 61 to 69 years,and 145 (41.5%) patients were aged 70 years or older.Except for the Eastern Cooperative Oncology Group performance status,clinical characteristics were comparable between the two groups.With a median follow-up of 82 (range,1-129) months,the 5-year overall survival (OS) and progression-free survival (PFS) rates were 51.9% and 45.8%,respectively.The 5-year OS rates for patients aged 61 to 69 years and those over 70 years were 58.3% and 42.8%(P =0.007),respectively,and the 5-year PFS rates were 51.0% and 38.6%(P =0.034).Treatment regimens including rituximab provided a higher 5-year OS rate (63.1% vs.37.1%,P < 0.001) and PFS rate (56.6% vs.31.8%,P < 0.001) than chemotherapy alone.For patients aged 61 to 69 years,chemotherapy plus rituximab resulted in a higher 5-year OS rate (66.7% vs.46.4%,P =0.002) and PFS rate (60.0% vs.38.1%,P =0.002) than chemotherapy alone.For patients aged ≥70 years,there was a marked survival advantage in patients who received chemotherapy plus rituximab (5-year OS rate:57.7% vs.25.4%,P < 0.001;5-year PFS rate:51.3% vs.23.9%,P < 0.001) compared with that seen in those who received chemotherapy alone.Multivariate analysis established that stage Ⅲ/Ⅳ disease,elevate 展开更多
关键词 ELDERLY DIFFUSE large B-CELL LYMPHOMA RITUXIMAB Prognosis
Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin:Analysis of 1,085 WHO classified cases in a single institution in China 预览
4
作者 Yuankai Shi Ying Han +12 位作者 Jianliang Yang Peng Liu Xiaohui He Changgong Zhang Shengyu Zhou Liqiang Zhou Yan Qin Yongwen Song Yueping Liu Shulian Wang Jing Jin Lin Gui Yan Sun 《中国癌症研究:英文版》 SCIE CAS CSCD 2019年第1期152-161,共10页
Objective: To explore the clinicobiologic features and outcomes of diffuse large B-cell lymphoma(DLBCL)patients in China according to the primary site.Methods: A total of 1,085 patients diagnosed with DLBCL in Nationa... Objective: To explore the clinicobiologic features and outcomes of diffuse large B-cell lymphoma(DLBCL)patients in China according to the primary site.Methods: A total of 1,085 patients diagnosed with DLBCL in National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College during a 6-year period were enrolled. Their clinical characteristics and outcomes were analyzed according to the primary site.Results: In the 1,085 patients, 679(62.6%) cases were nodal DLBCL(N-DLBCL) and 406 cases(37.4%) were extranodal DLBCL(EN-DLBCL). The most common sites of N-DLBCL were lymphonodus(64.8%), Waldeyer’s ring(19.7%), mediastinum(12.8%) and spleen(2.7%), while in EN-DLBCL, stomach(22.4%), intestine(16.0%),nose and sinuses(8.9%), testis(8.4%), skin(7.9%), thyroid(6.9%), central nervous system(CNS)(6.4%), breast(5.7%), bone(3.4%), and salivary gland(2.7%) were most common. N-DLBCL patients tend to present B symptoms, bulky disease, and elevated LDH more often, while age >60 years, extranodal sites >1, Ann Arbor stage I or II, bone marrow involvement, and Ki-67 index >90% were usually seen in EN-DLBCL. The 5-year overall survival(OS) rate and progression-free survival(PFS) rate for all patients were 62.5% and 54.2%. The 5-year OS rate for patients with N-DLBCL and EN-DLBCL were 65.5% and 56.9%(P=0.008), and the 5-year PFS were57.0% and 49.0%(P=0.020). Waldeyer’s ring originated DLBCL possessed the highest 5-year OS rate(83.6%) and PFS rate(76.9%) in N-DLBCL. The top five EN-DLBCL subtypes with favorable prognosis were stomach,breast, nose and sinuses, lung, salivary gland, with 5-year OS rate: 70.3%, 69.6%, 69.4%, 66.7% and 63.6%,respectively. While CNS, testis, oral cavity and kidney originated EN-DLBCL faced miserable prognosis, with 5-year OS rate of 26.9%, 38.2%, and 42.9%.Conclusions: In our study, primary sites were associated with clinical characteristics and outcomes. Compared with EN-DLBCL, N-DLBCL had better prognosis. 展开更多
关键词 DIFFUSE large B-CELL lymphoma(DLBCL) distribution NODAL EXTRANODAL
在线阅读 下载PDF
Inhibition of growth and metastasis of triple-negative breast cancer targeted by Traditional Chinese Medicine Tubeimu in orthotopic mice models 预览
5
作者 Jingxiao Wang Xinjie Yang +8 位作者 Haibo Han Limin Wang Weiqian Bao Shanshan Wang Robert M.Hoffman Meng Yang Hui Qi Chao An Kaiwen Hu 《中国癌症研究:英文版》 SCIE CAS CSCD 2018年第1期112-121,共10页
关键词 三元组 繁体中文 生长 否定 老鼠 模特儿 指向 聚合酶链反应
在线阅读 下载PDF
肠道菌群对结直肠癌发生发展的作用及中药干预的影响 预览 被引量:2
6
作者 顾艳芹 苏式兵 赵明 《世界科学技术:中医药现代化》 CSCD 2017年第4期590-595,共6页
结直肠癌(Colorectal Cancer,CRC)是常见的恶性肿瘤之一。越来越多的研究结果显示肠道菌群对结直肠癌的发生发展起着重要的作用,而中药对治理肠道菌群的紊乱有一定的调节作用。本文介绍了结直肠癌的肠道菌群变化,并从影响肠道黏膜屏... 结直肠癌(Colorectal Cancer,CRC)是常见的恶性肿瘤之一。越来越多的研究结果显示肠道菌群对结直肠癌的发生发展起着重要的作用,而中药对治理肠道菌群的紊乱有一定的调节作用。本文介绍了结直肠癌的肠道菌群变化,并从影响肠道黏膜屏障损伤、炎症以及细菌酶和毒性代谢产物等方面的机制,概括了肠道菌群紊乱对结直肠癌发生发展的影响,以及中药对肠道菌群的调节作用,为进一步研究结直肠癌和临床预防提供参考。 展开更多
关键词 中药 结直肠癌 肠道菌群 机制
在线阅读 下载PDF
Introduction of antineoplastic drug NSC631570 in an inpatient and outpatient setting:Comparative evaluation of biological effects 预览
7
作者 Mariia Rudyk Olexander Fedorchuk +2 位作者 Yaroslav Susak Yaroslav Nowicky Larysa Skivka 《亚洲药物制剂科学(英文)》 2016年第2期308-317,共10页
The aim of this study is to evaluate the effect of moderate physical exercise and treatment time on the organism’s response to NSC631570. The sensitivity of circulating phagocytes to the drug at different times of da... The aim of this study is to evaluate the effect of moderate physical exercise and treatment time on the organism’s response to NSC631570. The sensitivity of circulating phagocytes to the drug at different times of day was estimated in in vitro experiments. NSC631570 was administered intravenously to healthy volunteers (eleven men, 23 ± 2 years) in a single therapeutic dose in an inpatient and an outpatient setting. Blood samples were obtained before the drug administration, 30 min after the drug injection and every fourth hour throughout the 24 hour period. Biochemical parameters were determined using the hematological analyzer. Flow cytometry was used to evaluate phagocyte metabolism. Treatment of circulating phagocytes with NSC631570 in vitro resulted in an increase in ROS production along with a decrease in their phagocytic activity, most expressed in the morning time. Drug injection to sedentary persons resulted in pro-inflammatory metabolic polarization of circulating phagocytes. Introduction of NSC631570 to active persons was accompanied by a significant increase in phagocyte endocytosis along with a decrease in the daily mean of ROS generation. Significant oscillation (but in the normal ranges) of urea, creatinine, alanine aminotransferase and aspartate aminotransferase after NSC631570 introduction in the outpatient setting was shown during the day. Physical activity interferes with immunomodulatory action of NSC631570 and abrogates pro-inflammatory shift of circulating phagocytes. Biochemical parameters of blood from patients treated with NSC631570 in the outpatient setting must be interpreted cautiously considering the effect of physical activity on some metabolic biomarkers. 展开更多
关键词 NSC631570 Physical EXERCISE Blood BIOCHEMICAL parameters PHAGOCYTES functional POLARIZATION
在线阅读 下载PDF
Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma 预览
8
作者 Lin Gui Xiaohong Han +10 位作者 Xiaohui He Yuanyuan Song Jiarui Yao Jianliang Yang Peng Liu Yan Qin Shuxiang Zhang Weijing Zhang Wenlin Gai Liangzhi Xie Yuankai Shi 《中国癌症研究:英文版》 SCIE CAS CSCD 2016年第2期197-208,共12页
Objective: This study was designed to determine the safety, pharmacokinetics and biologic effects of a humanmouse chimeric anti-CD20 monoclonal antibody(SCT400) in Chinese patients with CD20-positive B-cell nonHodgkin... Objective: This study was designed to determine the safety, pharmacokinetics and biologic effects of a humanmouse chimeric anti-CD20 monoclonal antibody(SCT400) in Chinese patients with CD20-positive B-cell nonHodgkin's lymphoma(CD20+ B-cell NHL). SCT400 has an identical amino acid sequence as rituximab, with the exception of one amino acid in the CH1 domain of the heavy chain, which is common in Asians.Methods: Fifteen patients with CD20+ B-cell NHL received dose-escalating SCT400 infusions(250 mg/m~2: n=3; 375 mg/m~2: n=9; 500 mg/m~2: n=3) once weekly for 4 consecutive weeks with a 24-week follow-up period. The data of all patients were collected for pharmacokinetics and pharmacodynamics analyses.Results: No dose-limiting toxicities were observed. Most drug-related adverse events were grade 1 or 2. Two patients had grade 3 or 4 neutropenia. Under premedication, the drug-related infusion reaction was mild. A rapid, profound and durable depletion of circulating B cells was observed in all dose groups without significant effects on T cell count, natural killer(NK) cell count or immunoglobulin levels. No patient developed antiSCT400 antibodies during the course of the study. SCT400 serum half-life(T1/2), maximum concentration(Cmax) and area under the curve(AUC) generally increased between the first and fourth infusions(P<0.05). At the 375 mg/m~2 dose, the T1/2 was 122.5±46.7 h vs. 197.0±75.0 h, respectively, and the Cmax was 200.6±20.2 μg/m L vs. 339.1±71.0 μg/m L, respectively. From 250 mg/m~2 to 500 mg/m~2, the Cmax and AUC increased significantly in a dose-dependent manner(P<0.05). Patients with a high tumor burden had markedly lower serum SCT400 concentrations compared with those without or with a low tumor burden. Of the 9 assessable patients, 1 achieved complete response and 2 achieved partial responses.Conclusions: SCT400 is well-tolerated and has encouraging preliminary efficacy in Chinese patients with CD20+ B-cell NHL. 展开更多
关键词 单克隆抗体 淋巴瘤 中国人 患者 阳性 嵌合 药代动力学 氨基酸序列
在线阅读 下载PDF
Decreased Prognostic Value of International Prognostic Score in Chinese Advanced Hodgkin Lymphoma Patients Treated in the Contemporary Era
9
作者 Qin Wang Yan Qin +9 位作者 Su-Yi Kang Xiao-Hui He Peng Liu Sheng Yang Sheng-Yu Zhou Chang-Gong Zhang Lin Gui Jian-Liang Yang Yan Sun Yuan-Kai Shi 《中华医学杂志:英文版》 SCIE CAS CSCD 2016年第23期2780-2785,共6页
关键词 评分系统 淋巴瘤 预后 价值 患者 预测 晚期 国际
A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer 预览
10
作者 Xingsheng Hu Lin Wang +4 位作者 Lin Lin Xiaohong Han Guifang Dou Zhiyun Meng Yuankai Shi 《中国癌症研究:英文版》 SCIE CAS CSCD 2016年第4期444-451,共8页
Objective: This phase Ⅰ study was to evaluate safety, maximum tolerated dose, pharmacokinetics and preliminary antitumor activity of chidamide, a novel subtype-selective histone deacetylase(HDAC) inhibitor, in combin... Objective: This phase Ⅰ study was to evaluate safety, maximum tolerated dose, pharmacokinetics and preliminary antitumor activity of chidamide, a novel subtype-selective histone deacetylase(HDAC) inhibitor, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer(NSCLC).Methods: Ten patients received oral chidamide 20, 25, or 30 mg twice per week continuously with paclitaxel(175 mg/m~2) and carboplatin [area under the curve(AUC) 5 mg/m L/min] administered in a 3-week cycle. Patients with response and stable disease after four cycles maintained chidamide monotherapy until disease progression or unacceptable toxicity. Blood samples were collected for pharmacokinetic analysis after the first single oral of chidamide and first combination treatment in cycle 1 from all patients.Results: Two dose-limiting toxicities were recorded in the 30 mg cohort, including thrombocytopenia and prolonged neutropenia in the first cycle. Grade 3/4 neutropenia in any cycle was observed in all patients, but was not associated with significant complications. Other grade 3/4 hematologic toxicities included thrombocytopenia and leucopenia. No significant changes were observed in pharmacokinetic parameters for both chidamide and paclitaxel. One patient in the 20 mg cohort had confirmed partial response(PR). Two out of 5 patients with brain metastases had intracranial complete remission after 4-cycle treatment.Conclusions: Chidamide combined with paclitaxel and carboplatin was generally tolerated without unanticipated toxicities or clinically relevant pharmacokinetic interactions. The recommended dose for chidamide in this combination was established at 20 mg, and a phase Ⅱ trial is ongoing with this regimen in patients with advanced NSCLC. 展开更多
关键词 组蛋白去乙酰化酶 非小细胞肺癌 临床试验 酶抑制剂 紫杉醇 患者 卡铂 晚期
在线阅读 下载PDF
Pathobiology of ovarian carcinomas 预览
11
作者 Yuankai Shi Ping Zhou +11 位作者 Xiaohong Han Xiaohui He Shengyu Zhou Peng Liu Jianliang Yang Changgong Zhang Lin Gui Yan Qin Sheng Yang Liya Zhao Jiarui Yao Shuxiang Zhang 《癌症:英文版》 SCIE CAS CSCD 2015年第1期50-55,共6页
Ovarian tumors comprise a heterogeneous group of lesions, displaying distinct tumor pathology and oncogenic potentiel. These tumors are subdivided into three main categories: epithelial, germ cell, and sex-cord stroma... Ovarian tumors comprise a heterogeneous group of lesions, displaying distinct tumor pathology and oncogenic potentiel. These tumors are subdivided into three main categories: epithelial, germ cell, and sex-cord stromal tumors. We report herein the newly described molecular abnormalities in epithelial ovarian cancers(carcinomas). Immunohistochemistry and molecular testing help pathologists to decipher the significant heterogeneity of this disease. Our better understanding of the molecular basis of ovarian carcinomas represents the first step in the development of targeted therapies in the near future. 展开更多
关键词 卵巢癌 病理学 卵巢肿瘤 上皮细胞 分子检测 生殖细胞 免疫组化 靶向治疗
在线阅读 免费下载
Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma 预览
12
作者 Bo Jia Yuankai Shi +16 位作者 Suyi Kang Sheng Yang Shaoxuan Hu Yexiong Li Mei Dong Weihu Wang Jianliang Yang Liqiang Zhou Peng Liu Shengyu Zhou Yan Qin Lin Gui Changgong Zhang Hua Lin Shanshan Chen Lin Wang Xiaohui He 《中国癌症研究:英文版》 SCIE CAS CSCD 2015年第5期516-523,共8页
Background:The role of rituximab in combination with CHOP regimen in patients with stage I diffuse large B-cell lymphoma(DLBCL) remains to be defined.We aimed to compare CHOP plus rituximab(R-CHOP) with CHOP alone and... Background:The role of rituximab in combination with CHOP regimen in patients with stage I diffuse large B-cell lymphoma(DLBCL) remains to be defined.We aimed to compare CHOP plus rituximab(R-CHOP) with CHOP alone and determine the value of radiotherapy in these patients.Methods:Between 2003 and 2009,140 untreated patients with stage I DLBCL were retrospectively analyzed in this study.Results:Seventy-eight patients were treated in R-CHOP group and 62 in CHOP group.Ninety-one patients received additional radiotherapy at the end of chemotherapy.The different treatment groups were well-balanced with respect to baseline characteristics.Complete response(CR) rate was 77% both in R-CHOP and CHOP groups(P=0.945).After a median follow-up period of 56 months,patients received R-CHOP regimen had similar 5-year progression-free survival(PFS)(76%vs.85%;log-rank P=0.215)and 5-year overall survival(OS)(90%vs.96%;log-rank P=0.175) compared with those with CHOP alone.Patients with radiotherapy had significantly increased 5-year PFS compared with those who had chemotherapy alone(86%vs.71%;log-rank P=0.005).At multivariate analysis,patients who had CR(P=0.008) and received radiotherapy(P=0.003) were significantly associated with superior PFS.Conclusions:CHOP alone could be as effective as R-CHOP regimen and additional radiotherapy would be necessary for stage I or stage I non-bulky DLBCL patients. 展开更多
关键词 B细胞淋巴瘤 单核细胞 患者 单抗 放射治疗 多变量分析 PFS 放疗
在线阅读 下载PDF
Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas
13
作者 Ping Zhou Peng Liu Sheng-Yu Zhou Xiao-Hui He Xiao-Hong Han Yan Qin Sheng Yang Chang-Gong Zhang Lin Gui Jia-Rui Yao Li-Ya Zhao Shu-Xiang Zhang Yan Sun Yuan-KaiShi 《中华医学杂志:英文版》 SCIE CAS CSCD 2015年第18期2498-2504,共7页
关键词 造血干细胞移植 异环磷酰胺 足叶乙甙 淋巴瘤 外周血 患者 自体 基础
Autologous hematopoietic stem cell transplantation in chemotherapy-sensitive lymphoblastic lymphoma: treatment outcome and prognostic factor analysis 预览
14
作者 Youwu Shi Shengyu Zhou +16 位作者 Xiaohui He Xiaohong Han Shikai Wu Feng Pan Peng Liu Yinyu Liu Yingheng Lei Hongzhi Zhang Jianliang Yang Yan Qin Changgong Zhang Sheng Yang Liya Zhao Kehuan Luo Guanqing Wu Yan Sun Yuankai Shi 《中国癌症研究:英文版》 SCIE CAS CSCD 2015年第1期66-73,共8页
Objective: The study evaluated the effectiveness of autologous hematopoietic stem cell transplantation(AHSCT) in the treatment of lymphoblastic lymphoma(LL).Methods: We retrospectively analyzed the data from 41 patien... Objective: The study evaluated the effectiveness of autologous hematopoietic stem cell transplantation(AHSCT) in the treatment of lymphoblastic lymphoma(LL).Methods: We retrospectively analyzed the data from 41 patients with chemotherapy-sensitive LL who underwent hematopoietic stem cell transplantation(HSCT) from December 1989 to December 2009 in a single institution.Results: HSCT was conducted as first-line consolidation therapy and salvage therapy in 36 and 5 patients, respectively. The median follow-up was 97.1 months(range, 24.6-173.1 months). The 5-year overall survival(OS) and event-free survival(EFS) rate were 64% and 47% for the initially treated patients, respectively, and were both 20% for the relapsed ones. Bone marrow(BM) involvement and chemotherapy cycles prior to transplantation were identified as significant prognostic factors for EFS in multivariate analysis.Conclusions: These results confirm that AHSCT is a reasonable option for chemotherapy-sensitive LL patients in first complete remission(CR1). 展开更多
关键词 造血干细胞移植 治疗效果 淋巴瘤 母细胞 化疗 敏感 预后 自体
在线阅读 下载PDF
Enhancement of Sister Chromatid Exchanges in Peripheral Blood Lymphocytes of Thyroid Cancer Patients in Vitro 预览
15
作者 Kontou Maria Dafa Evagelia +2 位作者 Trivizaki Antoniou M. Elsa Iordanidou Lydia Lialiaris S. Theodore 《药剂与药理学:英文版》 2015年第4期173-181,共9页
关键词 药剂学 药理学 药学 数学 化学
在线阅读 下载PDF
PhaseⅠdose-finding study of sorafenib with FOLFOX4 as firstline treatment in patients with unresectable locally advanced or metastatic gastric cancer 预览
16
作者 Yihebali Chi 《中国癌症研究:英文版》 SCIE CAS CSCD 2015年第3期239-246,共8页
Objective: To determine the maximum tolerated dose(MTD), dose-limiting toxicity(DLT) and efficacy of sorafenib in combination with FOLFOX4(oxaliplatin/leucovorin(LV)/5-fluorouracil) as first-line treatment for advance... Objective: To determine the maximum tolerated dose(MTD), dose-limiting toxicity(DLT) and efficacy of sorafenib in combination with FOLFOX4(oxaliplatin/leucovorin(LV)/5-fluorouracil) as first-line treatment for advanced gastric cancer, we performed a phase I dose-finding study in nine evaluable patients with unresectable locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma. Methods: According to modified Fibonacci method, the design of this study was to guide elevation of the sorafenib dosage to the next level(from 200 mg twice daily to 400 mg twice daily and then, if tolerated, 600 mg twice daily). If the patient achieved complete response(CR), partial response(PR) or stable disease(SD) after eight cycles of treatment, combination chemotherapy was scheduled to be discontinued and sorafenib monotherapy continued at the original dose until either disease progression or unacceptable toxicity. Results: In sorafenib 200 mg twice daily group, DLT was observed in 1 of 6 patients, and in 400 mg twice daily group, it was observed in 2 of 3 patients. Seven of 9(77.8%) evaluable patients achieved PR, with a median overall survival(OS) of 11.8 [95% confidence interval(CI): 8.9-14.7] months. Common adverse effects include hand-foot syndrome, leukopenia, neutropenia, anorexia, and nausea.Conclusions: Twice-daily dosing of sorafenib 200 mg in combination with FOLFOX4 was proven effective and safe for the treatment of advanced gastric cancer, and could be an appropriate dosage for subsequent phase II clinical studies. 展开更多
关键词 治疗药物 转移性 剂量 患者 胃癌 晚期 白细胞减少 中性粒细胞
在线阅读 下载PDF
Screening and analysis of metabolic components in rat urine and feces after oral administration of total glycosides of Jinkuishenqi pills by HPLC-ESI/MSn 被引量:1
17
作者 LI Wen-Lan 《中国天然药物》 SCIE CAS CSCD 2013年第1期56-62,共7页
试图在 vivo 识别 Jinkuishenqi 药片和他们的代谢物的全部的 glycosides (TG ) 的化学部件。一个 HPLC-ESI-MS 方法在老鼠血浆为 TG 的代谢物的分析被开发的方法,在老鼠与 TG 被管理以后。18 混合物全部的结果 A 在 TG,其九是代谢物... 试图在 vivo 识别 Jinkuishenqi 药片和他们的代谢物的全部的 glycosides (TG ) 的化学部件。一个 HPLC-ESI-MS 方法在老鼠血浆为 TG 的代谢物的分析被开发的方法,在老鼠与 TG 被管理以后。18 混合物全部的结果 A 在 TG,其九是代谢物的口头的管理以后在尿被检测,其它是在 Jinkuishenqi 药片包含的混合物的原来的形式。在他们之中,代谢物是法国的酸, dehydromorroniaglycone, 2-hydroxyacetophenone-4-O-glucuronic 酸酉旨, paeonimetabolin 我, Mlog-2, Mlog-1, 2-hydroxy-4-methoxy acetophenone-5-O-sulfate, 2, 4-dihydroxyacetophenone 和一未知混合物分别地。20 混合物的一个总数在 TG,其八是代谢物的口头的管理以后在排汇物被检测,其它是在 Jinkuishenqi 药片包含的混合物的原来的形式。在他们之中,代谢物是法国的酸, swerosimetabolin A, paeonimetabolin 我, Mlog-2, Mmor-2, Mlog-1 和二未知混合物。用 HPLC-ESI-MS 的结论,在老鼠的 vivo 屏蔽并且分析 TG 的多重混合物和代谢物是可能的。这些代谢物的鉴定和结构说明为 TG 的有效性的进一步的药理学和机制提供了必要数据。 展开更多
Effect of Qinglongyi Polysaccharides on Complex Mobility of Erythrocytes in S180 Mice 被引量:1
18
作者 JI Chen-feng YUE Lei JI Yu-bin 《中草药:英文版》 CAS 2013年第1期58-61,共4页
Objective To study the effect of Qinglongyi polysaccharides (QP) in the exocarp of Juglans mandshurica on the complex mobility of erythrocytes in S180 mice. Methods Erythrocytes were collected and prepared into suspe... Objective To study the effect of Qinglongyi polysaccharides (QP) in the exocarp of Juglans mandshurica on the complex mobility of erythrocytes in S180 mice. Methods Erythrocytes were collected and prepared into suspensions, and the complex mobility of cells was measured using high performance capillary electrophoresis (HPCE). Optimized experimental conditions were as follows: 50 cm × 75 μm capillary, buffer for electrophoresis; phosphate solution containing hydroxypropylmethyl cellulose (0.1 mol/L, pH 7.4), injection pressure 3.448 kPa, injection time 10 s, separation voltage 20 kV, and column temperature 25 ℃. Results The migration time of erythrocytes in S180 mice was longer than that in normal mice, which was 18.09 min for the model group and 12.11 min for the control group, and the complex mobility of erythrocytes in S180 mice was lower than that in normal mice, which was 0.92 × 104 cm2 /(V·s) for the model group and 1.38 × 104 cm2 /(V·s) for the control group. It was also found that S180 mice treated by QP could shorten the migration time and increase the complex mobility of erythrocytes. Conclusion QP could improve the complex mobility of erythrocytes in S180 mice, and HPCE could be used as a powerful tool for determining the physiological state and functions of erythrocytes. 展开更多
关键词 complex mobility ERYTHROCYTE POLYSACCHARIDE QINGLONGYI S180 MICE
Antihepatocarcinoma Effect of Solanine and Its Mechanisms
19
作者 Yu-bin JI Shi-yong GAO 《中草药:英文版》 CAS 2012年第2期共10页
Objective To explore the antitumor effect of solanine and its mechanisms.Methods The in vivo antitumor effect of solanine was observed using models developed through in vivo transplantation of tumor cells; In vitro ... Objective To explore the antitumor effect of solanine and its mechanisms.Methods The in vivo antitumor effect of solanine was observed using models developed through in vivo transplantation of tumor cells; In vitro lines of sensitive antitumor cells were selected from the digestive system using MTT assay; The effect of solanine on cell morphology was observed using transmission electronic microscopy; The morphology of apoptotic cells was observed using Annexin V/PI double staining and laser confocal scanning microscopy (LCSM); The rate of cell apoptosis was measured using Annexin V/PI double staining and flow cytometry; The concentration of intracellular Ca2+ ([Ca2+]1) was determined using Fluo-3/AM staining and LCSM; The membrane potential of cellular mitochondria was determined using TMRE staining and LCSM; The protein expression of Bcl-2 and Bax was measured using immunological marking and LCSM; And the activity of caspase-3 was measured using the colorimetric method.Results Solanine could inhibit the growth of tumor weight in S180 tumor-bearing mice and prolong the survival time of H22 tumor-bearing mice.MTT assay revealed that HepG2 cells were quite sensitive to solanine because solanine could induce morphological changes in HepG2 cells,with the rate of early apoptosis being 4%,8.5%,and 20.1%,for HepG2 cells treated for 24 h with solanine at concentration of 0.4,2,and 10 μg/mL,respectively.Solanine could raise the [Ca2+]i and lower the membrane potential.It could reduce the protein expression of Bcl-2 while increase that of Bax,thus increasing the activity of caspase-3.Conclusion The obvious antitumor activity of sotanine in human hepatocarcinoma is demonstrated.This inhibitory effect is achieved through solanine decreasing the Bcl-2/Bax ratio,thus increasing [Ca2+]i,which could enhance the enzymatic activity of the caspase family,thus inducing the apoptosis of HepG2 cells. 展开更多
在在有局部地先进的直肠的癌症的病人的 neoadjuvant 时代的放射治疗的角色 预览
20
作者 Georgios V Koukourakis 《世界胃肠肿瘤学杂志:英文版(电子版)》 2012年第12期230-237,共8页
Surgery remains the primary determinant of cure in patients with localized rectal cancer, and total mesorectal excision is now widely accepted as standard of care. The widespread implementation of neoadjuvant shortco... Surgery remains the primary determinant of cure in patients with localized rectal cancer, and total mesorectal excision is now widely accepted as standard of care. The widespread implementation of neoadjuvant shortcourse radiotherapy (RT) or long-course chemoradiotherapy (CRT) has reduced local recurrence rates from 25% to 40% to less than 10%; Preoperative RT in resectable rectal cancer has a number of potential advantages, most importantly reducing local recurrence, and down-staging effect. In this article making a comprehensive literature review searching the reliable medical data bases of PubMed and Cochrane we present all available information on the role of radiation therapy alone or in combination with chemotherapy in preoperative setting of rectal cancer. Data reported show that in locally advanced rectal cancer the addition of radiation therapy or CRT pre surgically has significantly improved sphincter prevention surgery. Moreover, the addition of chemotherapy to radiation therapy in preoperative setting has significantly improved pathologic complete response rate and loco-regional control rate without improvement in sphincter preserving surgery. Finally, the results of recently published randomized trials have shown a significant improvement of prevs postoperative CRT on local control; however, there was no effect on overall survival. 展开更多
关键词 RECTAL cancer LOCALLY advanced PREOPERATIVE TREATMENT NEOADJUVANT TREATMENT RADIATION therapy
在线阅读 免费下载
上一页 1 2 3 下一页 到第
使用帮助 返回顶部 意见反馈